Pulmatrix merger progress with Eos SENOLYTIX; Form S-4 filed and near-term milestones
Aug 13, 2026, 8:19 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The S-4 filing and near-term merger closing (~Q3 2026) represent a concrete re-rating catalyst for Pulmatrix, especially if monetization channels for iSPERSE assets materialize (PUR1900/PUR3100/PUR1800) and overseas royalties via Cipla begin to accrue. However, execution risk and the ongoing going-concern note create downside risk; the stock has historically reacted to merger milestones and capital updates rather than operational data alone.
AI summary
What happened, with direct paths to the underlying reporting
Pulmatrix reported Q2 2026 results and updated on its merger with Eos SENOLYTIX, including the Form S-4 filing. The company highlights PUR1900, PUR3100, and PUR1800 assets, with India Phase 3 for PUR1900 led by Cipla and 2% royalties outside the US and 50/50 US rights. With $2.2M in cash and $0.7M restricted cash as of 6/30/2026, management says funds are sufficient to see the merger through and pursue licensing or monetization of assets.
S-4 filed for Pulmatrix-Eos merger; close expected Q3 2026.
Merger financing: $1.0M Series B private placement.
PUR1900 Phase 3 in India; Cipla to market outside US with 2% royalties.
Pulmatrix cash $2.2M; restricted cash $0.7M as of 6/30/2026.
R&D under $0.1M; all clinical development on hold pending licensing/monetization.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
